Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rosiglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 12/20 | 1.00 |
| ▸ | RARG | P13631 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rosiglitazone SCHEMBL504723 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL5734118 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL122053 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL29376790 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL466397 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL19469505 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL29757195 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL19023 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL5735765 | 0.99 | PPARG (0.98) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL2118157 | 0.99 | PPARG (0.98) | PPARGRARGRXRAPPARAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841460-A2 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007049098-A2 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-05-03 | — | — | WO | disclosed |
| EP-1585520-A1 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | Neurochem (International) Limited (CH) | 2005-10-19 | — | — | EP | disclosed |
| US-20050031651-A1 | Administering a combination of an agent that treats an amyloid-P disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2005-02-10 | — | — | US | disclosed |
| WO-2004058258-A1 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050031651-A1 | Administering a combination of an agent that treats an amyloid-P disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement | APP, IAPP, PSEN1 | PPARG 263/4885RARG 2379/4885RXRA 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.